Kurozumi, Sasagu http://orcid.org/0000-0002-9971-2918
Kaira, Kyoichi
Matsumoto, Hiroshi
Hirakata, Tomoko
Yokobori, Takehiko
Inoue, Kenichi
Horiguchi, Jun
Katayama, Ayaka
Koshi, Hiromi
Shimizu, Akira
Oyama, Tetsunari
Sloan, Erica K.
Kurosumi, Masafumi
Fujii, Takaaki
Shirabe, Ken
Funding for this research was provided by:
Australian National Health and Medical Research Council (APP1147498)
Article History
Received: 4 May 2019
Accepted: 29 June 2019
First Online: 9 July 2019
Compliance with ethical standards
:
: TY has received research grants from Ono Pharmaceutical Co., Ltd., CHUGAI Pharmaceutical Co., Ltd., and Memolead CO. KI has received a speaker honorarium from Eisai Co., Ltd., CHUGAI Pharmaceutical Co., Ltd., Pfizer Inc. KI has received research grants from Novartis Pharma K.K., Pfizer Inc., CHUGAI Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., PAREXEL/Puma Biotechnology, Merck Sharp & Dohme Ltd., Bayer Yakuhin, Ltd., Eli Lilly and Company, and Eisai Co., Ltd. EKS is a member of the scientific advisory board of Cygnal Therapeutics. MK received a speaker honorarium CHUGAI Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd. KS has received research grants from CHUGAI Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. The other authors declare that they have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from the participants included in the study.